The breast cancer advocacy foundation, Susan G Komen for the Cure, is actively promoting the need for copay-free germline breast cancer risk testing, at the state insurance level.
See a headline article at Precision Medicine Online (subscription) by Alison Kanski.
- Two bills became law in Arkansas and Tennessee.
- See TN HB1775 here.
- The newest three proposed bills have been introduced in 2026 by legislator advocates in Florida, Mississippi, and Tennessee. Proposed bills are also in play in Georgia, Illinois, and Minnesota.
National
National legislation, the Reducing Hereditary Cancer Act (HRCA), HR 4752, was introduced last summer by Rep. Wasserman-Schultz (FL).
USPSTF?
USPSTF guidelines lag, referring only to BRCA1-2. The current version is from 2019 (here), while an update has supposedly been underway since 2024 (here). However, its research plan only promised to re-evaluate BRCA 1&2 per se.
The March meeting of USPSTF was just canceled, meaning USPSTF has not met for a long time (here). MedpageToday recently published that HHS "may eliminate the USPSTF" here.
USPSTF guidelines are binding on commercial health insurance, per the ACA. State laws generally only impact fully-insured plans and not large employer self insured ("ASO") plans.
State Biomarker Bills
For the latest on state-level biomarker coverage bills in general, see fightcancer.org (ACS-CAN) here. A state biomarker law recently advanced to the governor's desk in Mississippi, here.
